Clinical Trial News and Research

RSS

Novel concept in chronic lymphoid leukemia treatment

Mayo Clinic researchers say they have moved closer to their goal of providing personalized care for a common blood cell cancer.

7 Nov 2008

GSK initiates major seasonal influenza vaccine efficacy trial

GlaxoSmithKline (GSK) announced today that it has started a worldwide clinical efficacy trial to evaluate an innovative vaccine for the prevention of seasonal influenza.

6 Nov 2008

SALVAT submits complete response to FDA approvable letter for CETRAXAL

SALVAT announced today the submission of the response to the FDA Approvable Letter for CETRAXAL (Ciprofloxacin 0.2% Otic Solution in Single Dose Containers).

6 Nov 2008

Nicotinamide, a form of vitamin B3, reduces Alzheimer's symptoms

An over-the-counter vitamin in high doses prevented memory loss in mice with Alzheimer's disease, and UC Irvine scientists now are conducting a clinical trial to determine its effect in humans.

5 Nov 2008

Investigational drug, MK-677 shows promise for reducing age-related frailty

Researchers at the University of Virginia Health System report that a daily single oral dose of an investigational drug, MK-677, increased muscle mass in the arms and legs of healthy older adults without serious side effects, suggesting that it may prove safe and effective in reducing age-related frailty.

5 Nov 2008

Safety and efficacy of febuxostat for gout examined

The goal in treating patients with gout is to reduce acute attacks by lowering serum urate levels, which are usually high in this disease.

5 Nov 2008

Anti-frailty pill for seniors in the pipeline

An 'anti-frailty' pill for seniors could be in the pipeline - the pill which increases muscle mass in arms and legs of older adults is the brainchild of researchers at the University of Virginia Health System.

5 Nov 2008

SurModics acquires drug delivery assets of PR Pharmaceuticals

SurModics, Inc. announced today that it has acquired a portfolio of intellectual property and collaborative drug delivery projects from PR Pharmaceuticals, Inc., a drug delivery company specializing in injectable, biodegradable sustained release formulations.

4 Nov 2008

Extended suboxone treatment substantially improves outcomes for opioid-addicted young adults

In the first clinical trial of a medication that was used for an extended time to treat opioid addiction in young adults, participants who received counseling and Suboxone (buprenorphine-naloxone) for 12 weeks had substantially better outcomes than those who received the standard treatment of short-term detoxification and counseling.

4 Nov 2008

Novel leukemia therapy shows promise for high-risk patients

Researchers at the Moores Cancer Center at the University of California, San Diego (UCSD) are conducting clinical trials of a novel therapy aimed at revving up the immune system to combat a particularly difficult-to-treat form of leukemia.

4 Nov 2008

YM Biosciences reports on early trials of nimotuzumab in brain metastases and high-grade glioma

YM BioSciences Inc. has announced data from two clinical trials of nimotuzumab, its humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Preliminary results from the two trials which are evaluating nimotuzumab in combination with radiation therapy for the treatment of brain metastases and high-grade gliomas, conducted by YM's licensor, were presented at the 2008 EORTC-NCI-AACR annual meeting recently held in Geneva, Switzerland.

3 Nov 2008

Halozyme Therapeutics starts phase 2 trial of insulin with rHuPH20 in type 1 diabetes

Halozyme Therapeutics, Inc. today announced it has started a Phase 2 study of proprietary recombinant human hyaluronidase enzyme (rHuPH20) co-formulations with Humulin R (regular insulin human injection) and with Humalog (insulin lispro) in Type 1 diabetic patients.

3 Nov 2008

MedImmune starts phase 1/2a clinical trial for respiratory syncytial virus vaccine

MedImmune today announced that it has initiated a Phase 1/2a clinical trial of a live, attenuated intranasal vaccine in healthy children one month to 12 months of age to help prevent severe respiratory syncytial virus (RSV) infections. RSV is the most common respiratory infection in infants and can cause disease in otherwise healthy infants and children.

3 Nov 2008

Genentech submits application to FDA for Avastin in the most aggressive form of brain cancer

Genentech has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin (bevacizumab) as a therapy for people with previously treated glioblastoma. If accepted by the FDA, the application would be considered for an accelerated approval that allows provisional approval of medicines for cancer or other life-threatening diseases based on preliminary evidence suggesting clinical benefit.

3 Nov 2008

Lithium carbonate to be tested for motor neurone disease

Victims of motor neurone disease (MND) will find hope from British research which has found that lithium carbonate, a cheap off-patent drug, may offer a treatment for the disease.

3 Nov 2008

Side effects predict succes of breast cancer treatment

Hot flushes, night sweats and painful joints can be a blessing in disguise for breast cancer patients - according to a new report published online in the Lancet Oncology.

2 Nov 2008

GlaxoSmithKline believes there is no liver safety issue with Avandia (rosiglitazone maleate)

GlaxoSmithKline today issued the following response to a petition filed by Public Citizen to the U.S. Food and Drug Administration (FDA) on Avandia (rosiglitazone maleate), a highly effective therapy for treating type 2 diabetes when used in the appropriate patient population.

31 Oct 2008